Investing.com — CureVac jumped 14% after the EU concluded a first round of talks for 225 million doses of a potential Covid-19 vaccine.
Curevac Bv (NASDAQ:CVAC) went public on Aug. 14, when it soared almost 250%. The company, backed by the Bill & Melinda Gates Foundation, is focused on using messenger RNA to treat diseases. The IPO raised more than $213 million.
The EU is also in talks with Johnson & Johnson (NYSE:JNJ) and Sanofi (NASDAQ:SNY) for their vaccines under development, and agreed last week an advanced purchase deal with AstraZeneca (NYSE:AZN) for at least 300 million doses of the shot it is developing with Oxford University, Reuters reported. CureVac said the talks included an option to supply 180 million additional doses.